Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00280436
Status:
COMPLETED
Last Update Posted:
2015-04-16
First Post:
2006-01-19
Brief Title:
Effects Of GW679769 On Sleep Onset And MaintenanceAnd Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Cross-over Study to Evaluate the Effects of GW679769 on Polysomnographic Sleep Recordings Subjective Sleep Assessment and Daytime Cognitive Function in Elderly and Non-elderly Subjects With Primary Insomnia
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to find the optimal best doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects with primary insomnia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None